In short
Ginkgo is the rare botanical whose flagship extract crossed over into medicine: standardised ginkgo is a registered medicinal product in several EU countries, holds well established use status at the European Medicines Agency, and sits on one of the largest trial literatures any plant has ever accumulated. In healthy adults, single doses improve the speed of attention for hours in controlled trials, and human imaging shows increased cerebral blood flow. The strongest clinical outcomes belong to higher doses in older adults, which we say plainly and do not borrow. The 60 mg here is the morning layer's circulation and speed component, at the exact specification the whole literature is built on.
Most botanicals would be lucky to have five controlled trials. Ginkgo has hundreds, a pharmacopoeia specification, and a legal status most of the supplement aisle can only imagine. That record is the starting point.
01The most studied leaf in the world
Ginkgo biloba is the oldest living tree species, and its standardised leaf extract is the most clinically examined botanical preparation in existence. The refined extract specification, 24 percent flavone glycosides and 6 percent terpene lactones, is not a marketing number: it is the definition under which ginkgo holds well established use status in the European Medicines Agency's herbal monograph and is registered as an actual medicinal product in countries including Germany and France.8 When this formulation states 50:1, 24 and 6 percent, it is naming the same material the clinical literature tested. That is what standardisation is for, as the standardisation page explains.
02What a single dose does
The healthy adult evidence people rarely quote is acute, and it is good. In a double blind crossover trial in healthy young adults, single doses of standardised ginkgo produced dose dependent improvements in the speed of attention, measurable from two and a half hours and sustained to six.1 A companion study found improved performance on demanding serial arithmetic under the same conditions.2 These are exactly the hours and exactly the demand profile a morning formulation cares about: not a memory transplant, a faster, steadier processing speed through the working morning.
03The circulation story
Ginkgo's oldest reputation is vascular, and modern imaging backs it in humans. In a controlled MR perfusion study, four weeks of ginkgo at 60 mg doses increased regional cerebral blood flow in healthy older adults.3 An earlier crossover trial measured ocular blood flow rising around 23 percent against placebo.4 The mechanisms are among the best mapped in the botanical world: platelet activating factor antagonism from the terpene lactones, vasoregulation, and flavonoid antioxidant activity.
Definition · The 24/6 specification
Standardised ginkgo extract concentrates the leaf roughly fifty fold and guarantees 24 percent flavone glycosides and 6 percent terpene lactones per dose. It is the specification behind the EMA monograph, the registered medicines, and the trial literature, and it is the specification in LAYER ONE.
04Where the strongest outcomes live
The heaviest clinical results sit at 240 mg daily in older adults with cognitive complaints: meta-analyses pooling thousands of patients find improved cognition and daily function against placebo, with tolerability indistinguishable from placebo.56 That is medicinal territory at medicinal doses, and this page does not borrow it; the honest note for younger healthy users is that chronic memory improvement has not replicated the way the acute attention effects have. What the whole body of work establishes for our purposes is different and valuable: decades of human data, a clean safety profile at scale, and a compound whose vascular and attentional signals keep reproducing.
05The research horizon
The literature is still moving. A 2025 meta-analysis reconfirmed efficacy and safety of the standardised extract across patient subgroups, and current work runs from perfusion imaging in healthy adults to combination studies with other standardised botanicals.7 Ginkgo is one of the few plants where new trials arrive yearly onto a foundation of hundreds, which means the picture sharpens rather than resets. This page moves with it.
06Why 60 mg, and why the morning
LAYER ONE carries twelve ingredients built around one job: a morning that comes up clean and holds. Ginkgo's 60 mg is the circulation and processing speed component of that architecture, at the studied specification, in the acute window the healthy adult trials describe. It is a deliberate supporting dose in a system, not a standalone intervention, and the system is the point. One practical note, stated once: ginkgo interacts with anticoagulant medication, and anyone on blood thinners should involve their doctor.
In the system
Ginkgo works the morning alongside citicoline and L-tyrosine, each covering a different part of the focus problem, as the comparison page maps. Build your protocol →
Sources
Next in this thread
Standardised extracts, explainedWhy the 24/6 specification is the whole story, and what a percentage guarantees.→How we handle evidence. This page is built on the endpoints where ginkgo performs in controlled trials, names the medicinal territory it does not borrow, and states its one interaction caution plainly. Educational content, not medical advice.